Resources

Respiratory syncytial virus (RSV) is a major, under–recognized public health problem causing more severe respiratory infections and hospitalizations in infants and young children each year than any other pathogen. New immunization tools now recommended for global use by the World Health Organization (WHO) could help change that.The opportunity to address this pervasive virus has never been better. To raise awareness, WHO and PATH have developed a toolkit of communication materials that public health stakeholders and advocates can use to share information about RSV disease, new prevention tools, and delivery considerations. Other expert contributors include the US Centers for Disease Control and Prevention, Seattle Children's Hospital/University of Washington, UMC Utrecht, the International Vaccine Access Center (IVAC), RRD Design, and more.To accommodate varying audience and engagement needs, this toolkit includes a stand-alone RSV primer presentation (and fact sheet) providing an overview of RSV disease and prevention options. Also available are modular PowerPoint slides that can be mixed and matched with the primer presentation to dive deeper into key topics for informing understanding and decision-making around RSV prevention. All slides come with speaker notes.Additional social media tools make sharing information about RSV with your network easy!To learn more about the toolkit, visit the web page.NOTE: Files available here as read-only. Editable files are readily available upon request. Please contact us.

The World Bank Group’s GFF × CIVIC partnership—a joint initiative of the Global Financing Facility for Women, Children and Adolescents (GFF) and the CIVIC: The Civil Society and Social Innovation Alliance—is supporting a consortium led by PATH, in partnership with the African Institute for Development Policy (AFIDEP) and the Organisation of African Youth (OAY), working together as VOICES (Voices Organizing for Inclusive Civic Engagement and Sustainability) to strengthen civil society engagement, coalition-building, and youth leadership around domestic resource mobilization for women’s, children’s and adolescent health and nutrition.To advance these objectives, the VOICES consortium will award subgrants to local CSOs and youth-led organizations in up to 22 African countries. Local CSOs and youth-led organizations are invited to apply as advocacy partnerships and help drive sustainable, accountable health investment for women, children, and adolescents.Learn more about the funding opportunity—with information available in English, French, and Portuguese—and contact us at voices@path.org with any questions. Applications close Wednesday, October 7th, 2026 at 23:59 East Africa Time.

This tool is designed to help global health stakeholders, procurers, and advocates estimate the annual operating expenditures (OPEX) of pressure swing adsorption (PSA) oxygen plants in low- and middle-income countries (LMICs). It is intended to support advocacy, planning, and comparative analysis related to oxygen system investments.The tool generates approximate operating cost estimates based on key PSA plant specifications and operating assumptions. Users should complete all input fields to the best of their ability using information available for the plant being assessed. Suggested values are provided for selected inputs to support users when site-specific information is unavailable.The estimates produced by this tool are intended to provide a standardized, evidence-informed basis for discussion and comparison across settings. The tool is not intended to serve as a detailed budgeting, procurement, or financial planning tool.

This is a simple, Excel-based tool for assessing and comparing costs of respiratory syncytial virus (RSV) intervention programs annually and for a period of five years with RSV maternal vaccine and monoclonal antibody (mAb) products available in the global market.It aims to help country-level policymakers compare products and estimate intervention program costs for both RSV maternal vaccine and mAbs. The tool can be used by decision-makers, implementers, technical partners, and others in any country, whether or not the country is eligible for co-funding from Gavi, the Vaccine Alliance.Product cost estimates (i.e., supplies procurement and international shipping) and immunization program costs (i.e., cost of delivery) are calculated separately for two perspectives: (1) the country perspective and (2) the combined country and donor/Gavi perspective (only relevant for Gavi-eligible countries). The tool also calculates the estimated cold chain volume requirements, which can support operational planning and logistics.It's important to note that cost is only one consideration when selecting an RSV intervention product, and users involved in decision-making around new vaccine introduction or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. Please be sure to check out this seven-minute tutorial video, which is in English, with French and Spanish subtitled versions also available. The tool is available to download in multiple languages below. For questions or support, contact PATH’s Health Economics & Outcomes Research Team: HEOR@path.org.

This document highlights the potential of intradermal vaccine delivery to improve vaccine equity through dose sparing, simplified administration, and expanded access. Learn about emerging ID injection technologies such as: autodisable ID needle and syringe, disposable-syringe jet injectors, and syringe-based hollow microneedle devices. Includes an overview of PATH’s work to assess the value, feasibility, and adoption of these innovations in low- and middle-income countries.